First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment

摘要: Abstract Background There has been tremendous progress regarding treatment options for hepatitis C virus (HCV) infection. Several interferon-free regimens are awaiting regulatory approval. These innovations promise substantial reductions in the burden of disease and side effects as well a decrease duration. Objectives The aim this quantitaitive study was to elicit patient preferences attributes innovative antiviral therapies C. Methods A systematic literature search 14 semi-structured interviews were performed, resulting eight patient-relevant characteristics. For discrete choice experiment, an experimental design (3×3 + 5×6) generated using Ngene software. survey conducted August 2014 through computer-assisted personal interviews. data effects-coded random parameter logit estimation. Results Participants patients with HCV (N = 561; 58.1% men) different states. analysis revealed predominance attribute "reaching sustained virological response." When considering confidence intervals, results showed three preference ranks. At first place "sustained response" (level difference [LD] 3.98), second "anemia" (LD 1.10), followed by "number interferon injections" 0.92), "rash" 0.82), "nausea and/or diarrhea" 0.79), "duration therapy" 0.78). last position occupied both "tiredness/fatigue" 0.31) "headache" 0.34). Conclusions From patients' point view, response is most essential criterion choosing therapy. It ranked at highest, dominating all modes administration. Furthermore, proved that consider probability occurrence severity treatment-induced effects. clearly valuation probabilities separate from severity.